Top Markets
#1 TENDIES TENDIES +46.86%
#2 Cash Cat Cash Cat +33.26%
#3 Threshold Network Threshold Network +19.02%
#4 Asteroid Shiba Asteroid Shiba +17.67%
#5 OSK OSK +15.80%
#6 龙虾 (Lobster) 龙虾 (Lobster) +13.42%
#7 Ape and Pepe Ape and Pepe +12.62%
#8 Magma Finance Magma Finance +11.22%
#9 MarsCoin MarsCoin +10.44%
#10 Kite Kite +9.98%
Coin of the day
TENDIES TENDIES
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.

AIM Vaccine Co., Ltd.

6660
Classifica tra le azioni #16560
Operating within the People's Republic of China, AIM Vaccine Co., Ltd.... Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
Prezzo delle azioni
$0.23346537
Capitalizzazione di mercato
$285.87M
Variazione (1 giorno)
6.41%
Variazione (1 anno)
-63.91%
Paese
CN
Scambia AIM Vaccine Co., Ltd. (6660)

Categoria

Healthcare
Utile per AIM Vaccine Co., Ltd. (6660)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di AIM Vaccine Co., Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di AIM Vaccine Co., Ltd. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH